Source: FierceHealthcare The Department of Justice has given the green light to insurance giant Cigna Corp.'s planned $67 billion acquisition of pharmacy benefit manager Express Scripts. The move terminates the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, one of the conditions necessary to close the deal, officials said in…...

Source: Allergan DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will…...

Source: FierceHealthcare Shareholders with both Cigna and Express Scripts voted to approve the insurer’s $67 billion acquisition of the PBM, the companies announced on Friday. The shareholder approval marks an important hurdle in finalizing the deal and follows several weeks in which Cigna tussled with activist investor Carl Icahn, momentarily…...

Source: FiercePharma Allergan, which is shopping assets to help turn its stock price around, has taken its first small step into selloff land. Spain’s Almirall said Friday it had agreed to pick up a portfolio of medical dermatology products from the Dublin drugmaker for up to $650 million in cash,…...

Source: Reuters FRANKFURT (Reuters) - Bayer has agreed to sell its established prescription dermatology brands to Denmark’s Leo Pharma, as the German drugmaker focuses on integrating seed maker Monsanto and on bolstering its drug development pipeline. The portfolio to be sold includes prescription skin creams against acne, fungal skin infections…...

 Source: Sienna Biopharmaceuticals Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.…...

Source: FierceBiotech A new CSO isn't all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British drugmaker's dermatology drug tapinarof in a deal worth up to £250 million ($330 million). The asset is poised to enter phase 3 in psoriasis and atopic dermatitis and is also…...

Source: Cassiopea Lainate, Italy – 10 July 2018 - Cassiopea SpA (SIX: SKIN), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® cream 1% (Clascoterone) demonstrated…...

Source: Reuters Amazon.com Inc said on Thursday it would buy small online pharmacy PillPack, a move that will put the world’s biggest online retailer in direct competition with drugstore chains, drug distributors and pharmacy benefit managers. The deal’s potential to disrupt major players across the drug supply chain nationwide prompted…...

Source: FierceBiotech Verrica Pharmaceuticals has filed to raise $86 million from public investors. The planned IPO will give Verrica the money it needs to take a treatment for viral skin infection molluscum through phase 3 and onto the market. West Chester, Pennsylvania-based Verrica’s lead candidate is VP-102, a drug-device combination.…...